(Reuters) -Sage Therapeutics claimed on Monday that its board has truly all denied the requisition deal it obtained from Biogen.
The agency claimed Biogen’s present to accumulate all distinctive shares of Sage that it doesn’t at the moment possess for $7.22 every, “significantly undervalues Sage and believes it is not in the best interest of shareholders.”
Biogen has a ten.2% danger in Sage Therapeutics.
Sage claimed it has truly launched a process to find tactical selections, nevertheless has not set up a schedule for the analysis process.
(Reporting by Sneha S Okay; Editing by Tasim Zahid)
